MedTrace Logo

Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A

NCT02989194 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2022-08-15

Study results available
· View outcomes & findings →

Summary

This is a Phase 2a randomized, double-blind, placebo-controlled study designed to assess the safety and tolerability of an investigational monoclonal antibody, VIS410, in subjects with uncomplicated influenza.

Conditions

Interventions

DRUG

VIS410 low dose

Single intravenous fixed low dose of VIS410

DRUG

VIS410 high dose

Single intravenous fixed high dose of VIS410

DRUG

Placebo

Single intravenous infusion of placebo

Sponsors & Collaborators

Principal Investigators

  • Clinical Development · Visterra, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-06
Primary Completion
2017-10-27
Completion
2017-10-27

Countries

  • United States
  • Bulgaria
  • Estonia
  • Latvia
  • Serbia
  • South Africa
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02989194 on ClinicalTrials.gov